Spyre halts RA program for anti-TL1A candidate after Phase 2 disappointment
Spyre Therapeutics is deprioritizing its anti-TL1A antibody for rheumatoid arthritis after the drug failed to meet the company's threshold for success in a mid-stage trial. The decision casts doubt on the broader potential of the candidate, though the company has not disclosed full results.
Expanded Detail
EXPANDED:
Spyre Therapeutics has decided to deprioritize its anti-TL1A antibody program for rheumatoid arthritis after the candidate failed to meet the company's internal success threshold in a Phase 2 trial. The company has not yet disclosed full trial results
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Endeavor reports mid-stage success for IPF drug with reversal potential · Drug development
NTX-253 Moves Toward Phase 2 Testing for Schizophrenia · Drug development
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data.” Browse more stories.